Evidence map›Paper›PMID 24914140›Full record

ReviewBlood2014

Acute graft-versus-host disease: a bench-to-bedside update.

Shernan G Holtan, Marcelo Pasquini, Daniel J Weisdorf

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02379442 (A Pilot Study of Early Treatment of Acute Graft Versus Host Disease With Bone Marrow- Derived Mesenchymal Stem Cells and Corticosteroids), which is not on this map. Cited by 115 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 6 pooled it
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02379442 phase1 / phase2terminatednot on this mapstarted 2015, after this paper: background citation

A Pilot Study of Early Treatment of Acute Graft Versus Host Disease With Bone Marrow- Derived Mesenchymal Stem Cells and Corticosteroids: Correlation of Disease Severity and Response With Biomarkers

TypeinterventionalSponsorNational Heart, Lung, and Blood Institute (NHLBI)Ran2015 to 2017Enrolled1ConditionsGraft-Versus-Host DiseaseArmsMSC
3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 6 syntheses or guidelines pooled it, 197 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Pooled it
  7. "They knew the same struggles": perceptions of a group coping skills intervention in patients with chronic graft-versus-host disease.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Decoding TNF receptor superfamily control of CD4Cell communication and signaling : CCS · 2026
    Review
  19. Article
  20. Article

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Shernan G HoltanBlood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN; and.
Marcelo PasquiniCenter for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI.
Daniel J WeisdorfBlood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN; and.
University of Minnesota · USMedical College of Wisconsin · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Scholars in Women's Health Research Across the LifespanK12HD043488 · NICHD · OREGON HEALTH & SCIENCE UNIVERSITY · PI MYATT, LESLIE · 2002 to 2023
$10.4M
NCI NIH HHS U24 CA076518NICHD NIH HHS 2K12HD043488-12NICHD NIH HHS K12 HD043488
6 · The paper itself

Abstract

Over the past 5 years, many novel approaches to early diagnosis, prevention, and treatment of acute graft-versus-host disease (aGVHD) have been translated from the bench to the bedside. In this review, we highlight recent discoveries in the context of current aGVHD care. The most significant innovations that have already reached the clinic are prophylaxis strategies based upon a refinement of our understanding of key sensors, effectors, suppressors of the immune alloreactive response, and the resultant tissue damage from the aGVHD inflammatory cascade. In the near future, aGVHD prevention and treatment will likely involve multiple modalities, including small molecules regulating immunologic checkpoints, enhancement of suppressor cytokines and cellular subsets, modulation of the microbiota, graft manipulation, and other donor-based prophylaxis strategies. Despite long-term efforts, major challenges in treatment of established aGVHD still remain. Resolution of inflammation and facilitation of rapid immune reconstitution in those with only a limited response to corticosteroids is a research arena that remains rife with opportunity and urgent clinical need.

Indexed as

Graft vs Host DiseaseAcute DiseaseAdrenal Cortex HormonesAllograftsAnimalsAntigen-Presenting CellsClinical Trials as TopicDisease Models, AnimalHematopoietic Stem Cell TransplantationHistocompatibility TestingHumansTissue DonorsT-LymphocytesTranslational Research, BiomedicalAdrenal Cortex Hormones

Identifiers

PMID24914140
PMCPMC4102709
OpenAlexW2321365245

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.